A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 601–700 of 3,965
Takehara, K., Koga, Y., Hachisu, Y., Utsugi, M., Sawada, Y., Saito, Y., Yoshimi, S., Yatomi, M., Shin, Y., Wakamatsu, I., et al. (2022) · Cells · doi:10.3390/cells11010143 · Cited by 64
Sisson, T. H., Christensen, P. J., Muraki, Y., Dils, A. J., Chibucos, L., Subbotina, N., Tohyama, K., Horowitz, J. C., Matsuo, T., Bailie, M., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13753 · Cited by 62
“Therefore, the approval of the first two drugs for patients with IPF, the prototypic scarring disorder of the lung, created excitement in the pulmonary community (King et al. 2014; Richeldi et al. 2014).”
BackgroundLewis, G. A., Schelbert, E. B., Naish, J. H., Bedson, E., Dodd, S. R., Eccleson, H., Clayton, D., Duran-Jimenez, B., McDonagh, T. A., Williams, S. G., et al. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06876-y · Cited by 69
Kim, G. H. J., Weigt, S. S., Belperio, J. A., Brown, M. S., Shi, Y., Lai, J. H., & Goldin, J. G. (2019) · European Radiology · doi:10.1007/s00330-019-06402-6 · Cited by 71
Kalluri, M., Luppi, F., & Ferrara, G. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.032 · Cited by 64
“Jo ur na l P re -p ro of measures such as lung function, and PROMs have only been used as secondary endpoints.(30,31) The past decade has seen an increase in PROMs use in idiopathic pulmonary fibrosis, generally including dyspnea and cough questionnaires, quality of life measures and depression/anxiety questionnaires.”
New insights into the Hippo/YAP pathway in idiopathic pulmonary fibrosis
Sun, M., Sun, Y., Feng, Z., Kang, X., Yang, W., Wang, Y., & Luo, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105635 · Cited by 72
Caminati, A., Madotto, F., Cesana, G., Conti, S., & Harari, S. A. (2015) · European Respiratory Review · doi:10.1183/16000617.0040-2015 · Cited by 72
Surolia, R., Li, F. J., Wang, Z., Li, H., Liu, G., Zhou, Y., Luckhardt, T., Bae, S., Liu, R.-M., Rangarajan, S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91377 · Cited by 69
The Role of Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Weng, D., Chen, X., Qiu, H., Zhang, Y., Li, Q., Zhao, M., Wu, Q., Chen, T., Hu, Y., Wang, L.-S., et al. (2019) · Mediators of Inflammation · doi:10.1155/2019/5160694 · Cited by 73
“While we do not have follow-up lung function data from all AE-IPF patients except the information about their death, our follow-up data of stable IPF patients show a one-year decline in FVC (270 ± 206ml) similar to recent studies [21, 22].”
ResultInterstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis
Hunninghake, G. M. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-212446 · Cited by 67
Management of Idiopathic Pulmonary Fibrosis
Pleasants, R., & Tighe, R. M. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019862497 · Cited by 63
The genetics of interstitial lung diseases
Borie, R., Guen, P. L., Ghanem, M., Taillé, C., Dupin, C., Dieudé, P., Kannengiesser, C., & Crestani, B. (2019) · European Respiratory Review · doi:10.1183/16000617.0053-2019 · Cited by 79
Yan, J., Wang, S.-Y., Su, Q., Zou, M.-W., Zhou, Z.-Y., Shou, J., & Huo, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-59093-7 · Cited by 62
Kramann, R., & Schneider, R. K. (2018) · Blood · doi:10.1182/blood-2018-02-834820 · Cited by 62
Intraindividual Response to Treatment with Pirfenidone in Idiopathic Pulmonary Fibrosis
Loeh, B., Drakopanagiotakis, F., Bandelli, G. P., von der Beck, D., Tello, S., Cordani, E., Rizza, E., Barrocu, L., Markart, P., Seeger, W., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201406-1106le · Cited by 62
Prognostic Value of Dual-Time-Point 18F-FDG PET for Idiopathic Pulmonary Fibrosis
Umeda, Y., Demura, Y., Morikawa, M., Anzai, M., Kadowaki, M., Ameshima, S., Tsuchida, T., Tsujikawa, T., Kiyono, Y., Okazawa, H., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.163360 · Cited by 62
Anti-fibrotic treatments for chronic liver diseases: The present and the future
Odagiri, N., Matsubara, T., Sato-Matsubara, M., Fujii, H., Enomoto, M., & Kawada, N. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0187 · Cited by 61
Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
Korfei, M., Mahavadi, P., & Guenther, A. (2022) · Cells · doi:10.3390/cells11101626 · Cited by 72
Luo, Y., Xu, W., Chen, H., Warburton, D., Dong, R., Qian, B., Selman, M., Gauldie, J., Kolb, M. R. J., & Shi, W. (2015) · The Journal of Pathology · doi:10.1002/path.4530 · Cited by 64
Kreuter, M., Herth, F. J. F., Wacker, M. E., Leidl, R., Hellmann, A., Pfeifer, M. A., Behr, J., Witt, S., Kauschka, D., Mall, M. A., et al. (2015) · BioMed Research International · doi:10.1155/2015/123876 · Cited by 77
Lung transplantation in idiopathic pulmonary fibrosis
Kumar, A., Kapnadak, S. G., Girgis, R. E., & Raghu, G. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1462704 · Cited by 76
Dutta, P., Funston, W., Mossop, H., Ryan, V., Jones, R., Forbes, R., Sen, S., Pearson, J. P., Griffin, S. M., Smith, J. A., et al. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-212102 · Cited by 69
Mammarappallil, J. G., Rankine, L. J., Wild, J. M., & Driehuys, B. (2019) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000392 · Cited by 67
Moor, C. C., Wijsenbeek, M. S., Balestro, E., Biondini, D., Bondue, B., Cottin, V., Flewett, R., Galvin, L., Jones, S., Molina‐Molina, M., et al. (2019) · ERJ Open Research · doi:10.1183/23120541.00124-2019 · Cited by 64
“A cure for IPF does not currently exist, although there are two approved drugs, pirfenidone and nintedanib, that slow disease progression [6, 7].”
Antoniou, K. M., Markopoulou, K., Tzouvelekis, A., Trachalaki, A., Vasarmidi, E., Organtzis, J., Tzilas, V., Bouros, E., Kounti, G., Rampiadou, C., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00172-2019 · Cited by 68
Lambers, C., Roth, M., Jaksch, P., Muraközy, G., Tamm, M., Klepetko, W., Ghanim, B., & Zhao, F. (2018) · Scientific Reports · doi:10.1038/s41598-018-19294-1 · Cited by 61
Spagnolo, P., Kreuter, M., Maher, T. M., Wuyts, W., Bonella, F., Corte, T. J., Kopf, S., Weycker, D., Kirchgaessler, K.-U., & Ryerson, C. J. (2018) · Respiration · doi:10.1159/000489668 · Cited by 61
Cheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01256 · Cited by 61
on behalf of the Trail Network, Solomon, J. J., Danoff, S. K., Goldberg, H. J., Woodhead, F., Kolb, M. R. J., Chambers, D. C., DiFranco, D., Spino, C., Haynes-Harp, S., et al. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01086-2 · Cited by 61
Ali, M. F., Egan, A. M., Shaughnessy, G. F., Anderson, D. K., Kottom, T. J., Dasari, H., Keulen, V. P. V., Aubry, M.-C., Yi, E. S., LIMPER, A. H., et al. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0387oc · Cited by 69
Icariin attenuates bleomycin-induced pulmonary fibrosis by targeting Hippo/YAP pathway
Du, W., Tang, Z., Yang, F., Liu, X., & Dong, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112152 · Cited by 65
Marijic, P., Schwarzkopf, L., Schwettmann, L., Ruhnke, T., Trudzinski, F. C., & Kreuter, M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01857-y · Cited by 71
Lou, Y., Zou, X., Pan, Z., Huang, Z., Zheng, S., Xiaowei, Z., Yang, X., Bao, M., Zhang, Y., Gu, J., et al. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae058 · Cited by 69
Peng, X., Moore, M. W., Mathur, A., Zhou, Y., Sun, H., Gan, Y., Herazo‐Maya, J. D., Kaminski, N., Hu, X., Pan, H., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201600373r · Cited by 65
“Whereas in some situations treatment with antifibrotic agents can attenuate the decline in ventilatory function caused by IPF, benefits are limited, heterogeneous, and accompanied by significant toxicities (9, 10).”
BackgroundIn the Shadow of Fibrosis: Innate Immune Suppression Mediated by Transforming Growth Factor-β
Thomas, B. J., Kan‐o, K., Loveland, K. L., Elias, J. A., & Bardin, P. G. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0248ps · Cited by 69
The role of high-resolution computed tomography in the follow-up of diffuse lung disease
Elicker, B. M., Kallianos, K. G., & Henry, T. S. (2017) · European Respiratory Review · doi:10.1183/16000617.0008-2017 · Cited by 63
Hariri, L. P., Adams, D. C., Wain, J. C., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201707-1446le · Cited by 61
Adegunsoye, A., Oldham, J. M., Bellam, S. K., Chung, J. H. N., Chung, P. A., Biblowitz, K., Montner, S. M., Lee, C. T., Hsu, S., Husain, A. N., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00255-2018 · Cited by 61
Nakano, A., Ohkubo, H., Taniguchi, H., Kondoh, Y., Matsuda, T., Yagi, M., Furukawa, T., Kanemitsu, Y., & Niimi, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-59100-5 · Cited by 70
Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging
Piñeiro-Hermida, S., Autilio, C., Martínez, P., Bosch, F., Pérez-Gil, J., & Blasco, M. A. (2020) · Journal of Cell Biology · doi:10.1083/jcb.202002120 · Cited by 60
Targeting Alveolar Repair in Idiopathic Pulmonary Fibrosis
Ptasinski, V., Stegmayr, J., Belvisi, M. G., Wagner, D. E., & Murray, L. A. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0476tr · Cited by 65
Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis
Wijsenbeek, M. S., Swigris, J. J., Inoue, Y., Kreuter, M., Maher, T. M., Suda, T., Baldwin, M., Mueller, H., Rohr, K. B., & Flaherty, K. R. (2023) · European Respiratory Journal · doi:10.1183/13993003.00752-2023 · Cited by 67
Self-citationHypoxia-sensitive pathways in inflammation-driven fibrosis
Manresa, M. C., Godson, C., & Taylor, C. T. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00349.2014 · Cited by 59
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
Conforti, F., Davies, E. R., Calderwood, C., Thatcher, T. H., Jones, M. G., Smart, D. E., Mahajan, S., Alzetani, A., Havelock, T., Maher, T. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17114 · Cited by 62
Treatment of Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis
Fidler, L. M., Sitzer, N., Shapera, S., & Shah, P. S. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.03.008 · Cited by 62
The dietary antioxidant quercetin reduces hallmarks of bleomycin-induced lung fibrogenesis in mice
Boots, A. W., Veith, C., Albrecht, C., Bartholomé, R., Drittij-Reijnders, M.-J., Claessen, S. M. H., Bast, A., Rosenbruch, M., Jonkers, L., van Schooten, F., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1142-x · Cited by 64
Corte, T. J., Lancaster, L., Swigris, J. J., Maher, T. M., Goldin, J. G., Palmer, S. M., Suda, T., Ogura, T., Minnich, A., Zhan, X., et al. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001026 · Cited by 59
Self-citationPamrevlumab for the treatment of idiopathic pulmonary fibrosis
Sgalla, G., Franciosa, C., Simonetti, J., & Richeldi, L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1773790 · Cited by 59
Maher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina‐Molina, M., Axmann, J., Kirchgaessler, K.-U., & Cottin, V. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000289 · Cited by 62
Self-citationRenaud, L., da Silveira, W. A., Takamura, N., Hardiman, G., & Feghali‐Bostwick, C. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00383 · Cited by 64
Cui, Y., Zhang, M., Leng, C., Blokzijl, T., Jansen, B. H., Dijkstra, G. D. H., & Faber, K. N. (2020) · Cells · doi:10.3390/cells9030775 · Cited by 66
“In a phase III randomized, double-blind, placebo-controlled, and multinational clinical trial (ASCEND), pirfenidone significantly improved progression-free survival and reduced the number of IPF patients who had a decline in forced vital capacity [17].”
BackgroundAgeing mechanisms that contribute to tissue remodeling in lung disease
Schuliga, M. J., Read, J. M., & Knight, D. A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101405 · Cited by 65
Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF
Ashley, S. L., Xia, M., Murray, S., O’Dwyer, D. N., Grant, E. P., White, E. S., Flaherty, K. R., Martínez, F. J., & Moore, B. B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159878 · Cited by 69
Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy
Leuschner, G., Stocker, F., Veit, T., Kneidinger, N., Winter, H., Schramm, R., Weig, T., Matthes, S., Ceelen, F., Arnold, P., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.07.002 · Cited by 59
Prasad, J. D., Mahar, A. M., Bleasel, J. F., Ellis, S. J., Chambers, D. C., Lake, F., Hopkins, P. M.-A., Corte, T. J., Allan, H., & Glaspole, I. (2017) · Respirology · doi:10.1111/resp.13163 · Cited by 65
Self-citationIdiopathic Pulmonary Fibrosis is a Genetic Disease Involving Mucus and the Peripheral Airways
Schwartz, D. A. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201802-144aw · Cited by 67
He, N., Bai, S., Huang, Y. L., Xing, Y., Chen, L., Yu, F., & Lv, C. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b00713 · Cited by 58
Hoffmann-Vold, A.-M., Weigt, S. S., Saggar, R., Palchevskiy, V., Volkmann, E. R., Liang, L. L., Ross, D., Ardehali, A., Lynch, J. P., & Belperio, J. A. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.050 · Cited by 58
Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis
Loveman, E., Copley, V. R., Scott, D. A., Colquitt, J. L., Clegg, A. J., & O’Reilly, K. M. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0034-y · Cited by 58
Lindell, K. O., Klein, S. J., Veatch, M. S., Gibson, K. F., Kass, D. J., Nouraie, M. S., & Rosenzweig, M. Q. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202012-1494oc · Cited by 67
Renal Fibrosis in Lupus Nephritis
Sciascia, S., Cozzi, M., Barinotti, A., Radin, M., Cecchi, I., Fenoglio, R., Mancardi, D., Jones, G. W., Rossi, D., & Roccatello, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214317 · Cited by 62
SPP1 induces idiopathic pulmonary fibrosis and NSCLC progression via the PI3K/Akt/mTOR pathway
Yue, B., Xiong, D., Chen, J., Yang, X., Zhao, J., Shao, J., Wei, D., Gao, F., Huang, M., & Chen, J. (2024) · Respiratory Research · doi:10.1186/s12931-024-02989-7 · Cited by 74
Duck, A., Pigram, L., Errhalt, P., Ahmed, D., & Chaudhuri, N. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0183-7 · Cited by 67
Interstitial lung disease in systemic sclerosis
Wells, A. U. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.08.002 · Cited by 63
TWEAK-Fn14 Signaling Activates Myofibroblasts to Drive Progression of Fibrotic Kidney Disease
Gomez, I. G., Roach, A. M., Nakagawa, N., Amatucci, A., Johnson, B. G., Dunn, K., Kelly, M. C., Karaca, G., Zheng, T. S., Szak, S. T., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015111227 · Cited by 62
Lucarini, L., Durante, M., Lanzi, C., Pini, A., Boccalini, G., Calosi, L., Moroni, F., Masini, E., & Mannaioni, G. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12967 · Cited by 57
Role of IL-17A in murine models of COPD airway disease
Yanagisawa, H., Hashimoto, M., Minagawa, S., Takasaka, N., Ma, R., Moermans, C., Ito, S., Araya, J., Budelsky, A., Goodsell, A., et al. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00301.2016 · Cited by 61
Lin, C., Borensztajn, K., & Spek, C. A. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13623 · Cited by 66
Multidisciplinary evaluation of interstitial lung diseases: current insights
Walsh, S. L. F. (2017) · European Respiratory Review · doi:10.1183/16000617.0002-2017 · Cited by 69
BRD4 inhibition for the treatment of pathological organ fibrosis
Stratton, M. S., Haldar, S. M., & McKinsey, T. A. (2017) · F1000Research · doi:10.12688/f1000research.11339.1 · Cited by 58
Korfei, M., Stelmaszek, D., MacKenzie, B., Skwarna, S., Chillappagari, S., Bach, A., Ruppert, C., Saito, S., Mahavadi, P., Klepetko, W., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207915 · Cited by 64
“ity); but these effects were well tolerated in patients participating in clinical trials, especially when the dose was decreased [3,58].”
BackgroundMetabolic Reprogramming as a Driver of Fibroblast Activation in PulmonaryFibrosis
Para, R., Romero, F., George, G., & Summer, R. S. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.02.003 · Cited by 68
Mortality Trends of Idiopathic Pulmonary Fibrosis in the United States From 2004 Through 2017
Jeganathan, N., Smith, R. A., & Sathananthan, M. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.08.016 · Cited by 63
Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies
Selvarajah, B., Platé, M., & Chambers, R. C. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101227 · Cited by 57
A New Hope for Idiopathic Pulmonary Fibrosis
Hunninghake, G. M. (2014) · New England Journal of Medicine · doi:10.1056/nejme1403448 · Cited by 57
Self DNA perpetuates IPF lung fibroblast senescence in a cGAS-dependent manner
Schuliga, M. J., Read, J. M., Blokland, K. E. C., Waters, D. W., Burgess, J. K., Prêle, C. M., Mutsaers, S. E., Jaffar, J., Westall, G. P., Reid, A. T., et al. (2020) · Clinical Science · doi:10.1042/cs20191160 · Cited by 62
“some patients, do not reverse fibrosis, are expensive and have significant side-effects [3, 4].”
BackgroundKhan, F. A., Stewart, I., Saini, G., Robinson, K. A., & Jenkins, R. G. (2022) · European Respiratory Journal · doi:10.1183/13993003.01612-2021 · Cited by 57
Chae, K. J., Chung, M. J., Jin, G. Y., Song, Y. J., An, A. R., Choi, H., & Goo, J. M. (2022) · European Radiology · doi:10.1007/s00330-021-08378-8 · Cited by 58
Bennett, D., Fossi, A., Bargagli, E., Refini, R. M., Pieroni, M., Luzzi, L., Ghiribelli, C., Paladini, P., Voltolini, L., & Rottoli, P. (2015) · Lung · doi:10.1007/s00408-015-9767-x · Cited by 61
Bellaye, P., Shimbori, C., Upagupta, C., Sato, S., Shi, W., Gauldie, J., Ask, K., & Kolb, M. R. J. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0252oc · Cited by 59
Yang, L., Liu, G., Li, X., Xia, Z., Wang, Y., Lin, W., Zhang, W., Zhang, W., & Li, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03027-2 · Cited by 57
Screening for Lung Cancer: Incidental Pulmonary Parenchymal Findings
Chung, J. H., Richards, J. C., Koelsch, T. L., et al. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.17.19003 · Cited by 56
Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice
Li, X., Bi, Z., Liu, S., Gao, S., Cui, Y., Huang, K., Huang, M., Mao, J., Li, L., Gao, J., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01021 · Cited by 59
Checa, J., & Aran, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239317 · Cited by 61
Tahara, M., Fujino, Y., Yamasaki, K., Oda, K., Kido, T., Sakamoto, N., Kawanami, T., Kataoka, K., Egashira, R., Hashisako, M., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01671-6 · Cited by 67
Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling
Gu, L., Surolia, R., Larson‐Casey, J. L., He, C., Davis, D., Kang, J., Antony, V. B., & Carter, A. B. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00840-w · Cited by 61
Challenges for Clinical Drug Development in Pulmonary Fibrosis
White, E. S., Thomas, M. J., Stowasser, S., & Tetzlaff, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.823085 · Cited by 71
“, 2012) finally enabled a breakthrough in the treatment of patients with this devastating disease with the approval of nintedanib and pirfenidone (Richeldi et al., 2011; Raghu et al., 2012; King et al., 2014).”
BackgroundKou, M., Jiao, Y., Li, Z., Wei, B., Li, Y., Cai, Y., & Wei, W. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03720-7 · Cited by 79
A Critical Role for the mTORC2 Pathway in Lung Fibrosis
Chang, W., Wei, K., Ho, L. A., Berry, G. J., Jacobs, S. S., Chang, C. H., & Rosen, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106155 · Cited by 56
Lee, S. M., Seo, J. B., Oh, S. Y., Kim, T. H., Song, J. W., Lee, S. M., & Kim, N. (2017) · European Radiology · doi:10.1007/s00330-017-5028-0 · Cited by 61
Ntolios, P., Manoloudi, E., Tzouvelekis, A., Bouros, E., Steiropoulos, P., Anevlavis, S., Bouros, D., & Froudarakis, M. E. (2018) · The Clinical Respiratory Journal · doi:10.1111/crj.12777 · Cited by 56
Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis
LANCASTER, L. H. (2018) · Multidisciplinary Respiratory Medicine · doi:10.1186/s40248-018-0158-z · Cited by 80
Self-citationBärnthaler, T., Theiler, A., Zabini, D., Trautmann, S., Stacher‐Priehse, E., Lanz, I., Klepetko, W., Sinn, K., Flick, H., Scheidl, S. J., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.11.032 · Cited by 61
Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre
Raghu, G., Morrow, E. H., Collins, B. F., Ho, L. A., Hinojosa, M. W., Hayes, J. M., Spada, C. A., Oelschlager, B. K., Li, C., Yow, E. S., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00488-2016 · Cited by 55
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
Fischer, A., & Distler, J. H. W. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04720-0 · Cited by 63
Roach, K. M., & Bradding, P. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14939 · Cited by 68
Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis
Assayag, D., Morisset, J., Johannson, K. A., Wells, A. U., & Walsh, S. L. F. (2020) · Thorax · doi:10.1136/thoraxjnl-2019-213968 · Cited by 54
Wang, H., Chen, M., Sang, X., You, X., Wang, Y., Paterson, I. C., Hong, W., & Yang, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112154 · Cited by 59
Hermansky–Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease
Yokoyama, T., & Gochuico, B. R. (2021) · European Respiratory Review · doi:10.1183/16000617.0193-2020 · Cited by 60
Marinescu, D.-C., Raghu, G., Rémy‐Jardin, M., Travis, W. D., Adegunsoye, A., Beasley, M. B., Chung, J. H., Churg, A., Cottin, V., Egashira, R., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.06.013 · Cited by 61
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.